Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.

Tph cells are linked to the severity of systemic lupus erythematosus.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.

Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.

Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.

Early recognition and treatment of SLE can improve outcomes in patients with complex symptoms.

Certain proteins involved in DNA modification may affect the genetic changes in systemic lupus erythematosus and could indicate the disease's activity.

Choosing the right tools is crucial for accurately measuring lupus activity and damage.

Chinese patients with systemic lupus erythematosus commonly experience oral ulcers, arthritis, alopecia, skin rash, and nephritis.

Skin problems are common in lupus patients and should be treated early to prevent worsening.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Psychosis can be an early sign of neuropsychiatric lupus, treatable with tailored medication.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.

Hair loss in systemic lupus erythematosus patients is unique and improves with treatment.

Certain skin symptoms can help detect and manage systemic lupus.

Early detection and targeted management are crucial for better outcomes in systemic lupus erythematosus.

Absence of skin rash and low complement C3 levels increase the risk of lupus nephritis.

Hair chemicals don't cause SLE but may increase skin issues in those with SLE.

Belimumab may cause hair loss in lupus patients.

Fever and rash can be early signs of lupus.

Adding colchicine stopped the girl's recurring heart issues caused by lupus.